文献速递甲状腺疾病

全球63个国家2013-17年甲状腺癌流行病学模式演变与过度诊断估计:一项基于人群的研究

Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013-17 in 63 countries worldwide: a population-based study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-10-07

该研究基于国际癌症研究机构全球癌症观察站数据库,分析1980至2017年63个国家甲状腺癌发病与死亡趋势。2013-17年间,2 297 057例甲状腺癌中1 736 133例(75.6%)归因于过度诊断,女性1 368 181例、男性367 952例,过度诊断程度从无到女性超过85.0%不等。

要点

  • 1980-2017年多数国家甲状腺癌发病率上升,2010年代初后韩国、美国等部分国家出现下降趋势。
  • 2013-17年全球2 297 057例甲状腺癌中1 736 133例(75.6%)为过度诊断,女性占1 368 181例。
  • 过度诊断程度国家间差异大,从无过度诊断到女性超过85.0%的病例为过度诊断。

核心结论

  • 尽管部分高收入国家甲状腺癌发病率已趋于平稳或下降,但过度诊断的规模仍然很大,且正快速向转型国家扩展,构成需要应对的全球公共卫生挑战。

研究设计与样本

  • 从国际癌症研究机构全球癌症观察站数据库获取数据,长期发病数据来自CI5 plus中43个国家97个登记处,2013-17年病例数据来自CI5-XII中63个国家385个登记处,死亡数据来自WHO。
  • 采用直接年龄标准化法(以世界人口为参照)估计甲状腺癌发病与死亡的年龄标准化率,并使用既往开发并验证的方法估计过度诊断病例数并外推至全国。

主要发现

  • 1980-2017年多数国家甲状腺癌发病率上升,女性发病率最高见于韩国、塞浦路斯、厄瓜多尔、中国和土耳其,男性亦见于上述国家。
  • 2010年代初之前呈上升趋势,此后韩国、美国、加拿大、以色列及法国、意大利、奥地利、爱尔兰等部分西欧国家出现下降趋势。
  • 女性最高与最低发病率之差从1980年代初的小于10.0/10万增至2012年的101.4/10万;男性该差值在研究期间为2.7/10万至23.5/10万。
  • 死亡率远低于发病率,研究期间男女最高与最低死亡率之差约为1.0-2.0/10万。
  • 2013-17年期间甲状腺乳头状癌 contribute 了甲状腺癌年龄标准化发病率的大部分变异;大多数国家年龄别发病率呈倒U形,而死亡率随年龄增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of thyroid cancer has been increasing in many countries, mainly due to overdiagnosis. Given these rapid changes, we aim to assess the specific features of the thyroid cancer diagnosis epidemic and provide estimates of overdiagnosis across countries spanning five continents and identify areas in which coping strategies are needed. METHODS: Two types of data were retrieved from the International Agency for Research on Cancer (IARC) Global Cancer Observatory database. The long-term annual incidence of thyroid cancer by sex and 5-year age group for all ages from 1980 to 2017 was obtained from continuous population-based registries available in the Cancer Incidence in Five Continents (CI5) plus, with 97 registries from 43 countries selected. Sex-age-specific thyroid cancer cases, overall and by subtype, along with corresponding population counts were retrieved from all registries included in the latest volume of CI5 (CI5-XII), with 385 registries in 63 countries. Annual mortality data from 1980 to 2022 were obtained from WHO, with population counts supplemented by UN population estimates. We estimated age-standardised rates (ASRs) of thyroid cancer incidence and mortality for all ages by sex using direct age standardisation, with the world population as a reference. Long-term annual trends of ASRs were compared between incidence and mortality since 1980. Subtype distribution was calculated for thyroid cancer incidence during 2013-17. We estimated the numbers of thyroid cancer cases and overdiagnosed cases and extrapolated to the whole country using a previously developed and validated method. FINDINGS: Thyroid cancer incidence rates rose during 1980-2017 for most countries, with the highest rates seen in South Korea, Cyprus, Ecuador, China, and Türkiye for females and males. An upward trend was seen until the early 2010s, followed by a downward trend in South Korea, the USA, Canada, and Israel and some Western European countries, such as France, Italy, Austria, and Ireland. The difference between the highest and lowest incidence rates ranged from less than 10·0 per 100 000 females in the early 1980s to 101·4 per 100 000 females in 2012. For males, the difference between the highest and lowest incidence rates ranged from 2·7 per 100 000 to 23·5 per 100 000 over the study period. Mortality rates were substantially lower, with a difference between the highest and lowest rates across countries of around 1·0-2·0 per 100 000 for both sexes throughout the study period. During 2013-17, papillary thyroid cancer contributed to the large variation in ASRs of thyroid cancer incidence. The mortality rates of thyroid cancer increased with age for all countries, whereas the observed age-specific incidence rates showed an inverted U-shape in most countries. The magnitude of overdiagnosis varied across countries, ranging from no overdiagnosis (in Uganda, Zimbabwe, and Trinidad and Tobago) to more than 85·0% of thyroid cancer cases being overdiagnosed in females (in Cyprus, China, South Korea, and Türkiye). Overall, 1 736 133 (75·6%) of 2 297 057 cases were attributable to overdiagnosis, including 1 368 181 females and 367 952 males. INTERPRETATION: Although the incidence of thyroid cancer has reached a plateau or decrease in some high-income countries, the magnitude of overdiagnosis is still very large and the expansion of overdiagnosis of thyroid cancer to the transitioning countries has been rapid, which makes it a global public health challenge that needs to be addressed. FUNDING: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Young Talents Program of Sun Yat-sen University Cancer Center, Italian Association for Cancer Research, and the Italian Ministry of Health (Ricerca Corrente).

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Li M, Dal Maso L, Pizzato M, et al. Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013-17 in 63 countries worldwide: a population-based study. Lancet Diabetes Endocrinol. 2024. PMID: 39389067. doi:10.1016/S2213-8587(24)00223-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。